Compare HMY & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMY | SNN |
|---|---|---|
| Founded | 1950 | 1856 |
| Country | South Africa | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Industrial Specialties |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 13.9B |
| IPO Year | N/A | 1999 |
| Metric | HMY | SNN |
|---|---|---|
| Price | $20.71 | $33.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | $16.00 | ★ $32.83 |
| AVG Volume (30 Days) | ★ 3.6M | 611.1K |
| Earning Date | 02-04-2016 | 02-24-2026 |
| Dividend Yield | 0.81% | ★ 2.18% |
| EPS Growth | ★ 67.74 | 59.91 |
| EPS | ★ 1.29 | 0.56 |
| Revenue | $4,161,584,110.00 | ★ $5,944,000,000.00 |
| Revenue This Year | $40.10 | $7.71 |
| Revenue Next Year | $14.83 | $5.23 |
| P/E Ratio | ★ $15.84 | $29.19 |
| Revenue Growth | ★ 20.39 | 5.35 |
| 52 Week Low | $8.95 | $23.69 |
| 52 Week High | $22.25 | $38.79 |
| Indicator | HMY | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 53.70 |
| Support Level | $20.16 | $33.53 |
| Resistance Level | $21.47 | $34.21 |
| Average True Range (ATR) | 0.68 | 0.43 |
| MACD | -0.11 | 0.16 |
| Stochastic Oscillator | 56.25 | 65.36 |
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.